| HOME >> BIOLOGY >> TECHNOLOGY |
30, 2007, on an adjusted cash basis, are dilutive shares consisting of
1,796,000 common stock equivalent shares from the potential exercise of
stock options and warrants. Potential dilutive shares consisting of
761,000 common stock equivalent shares from the potential conversion of
convertible debt securities for the six months ended June 30, 2007 were
not used in the calculation of diluted net income per common share, on an
adjusted cash basis, because inclusion thereof would be antidilutive.
Inverness Medical Innovations, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in $000s)
June 30, December 31,
2008 2007
(unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $167,234 $414,732
Restricted cash 3,401 141,869
Marketable securities 1,864 2,551
Accounts receivable, net 256,118 163,380
Inventories, net 180,248 148,231
Prepaid expenses and other current assets 121,566 82,211
Total current assets 730,431 952,974
PROPERTY, PLANT AND EQUIPMENT, NET 285,916 267,880
GOODWILL AND OTHER INTANGIBLE ASSETS, NET 4,793,183 3,494,174
DEFERRED FINANCING COSTS AND OTHER
ASSETS, NET 132,537 165,731
Total assets $5,942,067 $4,880,759
LIABILITIES AND STOCKHOLDERS' EQUITY
CU
'/>"/>
| SOURCE Inverness Medical Innovations, Inc. Copyright©2008 PR Newswire. All rights reserved |